140 related articles for article (PubMed ID: 9437715)
1. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.
Vertongen P; Schiffmann SN; Gourlet P; Robberecht P
Peptides; 1997; 18(10):1547-54. PubMed ID: 9437715
[TBL] [Abstract][Full Text] [Related]
2. Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors.
Gourlet P; Vandermeers A; Van Rampelbergh J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():247-52. PubMed ID: 9928018
[TBL] [Abstract][Full Text] [Related]
3. Development of high affinity selective VIP1 receptor agonists.
Gourlet P; Vandermeers A; Vertongen P; Rathe J; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1539-45. PubMed ID: 9437714
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
Simonneaux V; Kienlen-Campard P; Loeffler JP; Basille M; Gonzalez BJ; Vaudry H; Robberecht P; Pévet P
Neuroscience; 1998 Aug; 85(3):887-96. PubMed ID: 9639281
[TBL] [Abstract][Full Text] [Related]
5. The long-acting vasoactive intestinal polypeptide agonist RO 25-1553 is highly selective of the VIP2 receptor subclass.
Gourlet P; Vertongen P; Vandermeers A; Vandermeers-Piret MC; Rathe J; De Neef P; Waelbroeck M; Robberecht P
Peptides; 1997; 18(3):403-8. PubMed ID: 9145428
[TBL] [Abstract][Full Text] [Related]
6. Autoradiographic visualization of CNS receptors for vasoactive intestinal peptide.
Shaffer MM; Moody TW
Peptides; 1986; 7(2):283-8. PubMed ID: 3016682
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
Juarranz MG; De Neef P; Robberecht P
Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
[TBL] [Abstract][Full Text] [Related]
8. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 1997; 18(10):1555-60. PubMed ID: 9437716
[TBL] [Abstract][Full Text] [Related]
9. Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain.
Martin JL; Dietl MM; Hof PR; Palacios JM; Magistretti PJ
Neuroscience; 1987 Nov; 23(2):539-65. PubMed ID: 3437978
[TBL] [Abstract][Full Text] [Related]
10. Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain.
Vertongen P; Schiffmann SN; Gourlet P; Robberecht P
Ann N Y Acad Sci; 1998 Dec; 865():412-5. PubMed ID: 9928040
[No Abstract] [Full Text] [Related]
11. Vasoactive intestinal polypeptide (VIP) phase-shifts the rat suprachiasmatic nucleus clock in vitro.
Reed HE; Meyer-Spasche A; Cutler DJ; Coen CW; Piggins HD
Eur J Neurosci; 2001 Feb; 13(4):839-43. PubMed ID: 11207820
[TBL] [Abstract][Full Text] [Related]
12. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes.
Jiang X; Wang HY; Yu J; Ganea D
Ann N Y Acad Sci; 1998 Dec; 865():397-407. PubMed ID: 9928038
[TBL] [Abstract][Full Text] [Related]
13. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors.
Gourlet P; Rathé J; De Neef P; Cnudde J; Vandermeers-Piret MC; Waelbroeck M; Robberecht P
Eur J Pharmacol; 1998 Jul; 354(1):105-11. PubMed ID: 9726637
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes.
Gourlet P; Vandermeers-Piret MC; Rathé J; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Eur J Pharmacol; 1998 May; 348(1):95-9. PubMed ID: 9650836
[TBL] [Abstract][Full Text] [Related]
15. Influence of selective VIP receptor agonists in the rat gastric fundus.
Robberecht P; De Neef P; Lefebvre RA
Eur J Pharmacol; 1998 Oct; 359(1):77-80. PubMed ID: 9831296
[TBL] [Abstract][Full Text] [Related]
16. Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands.
Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
Mol Pharmacol; 1999 Dec; 56(6):1280-7. PubMed ID: 10570056
[TBL] [Abstract][Full Text] [Related]
17. Autoradiographic analysis of the distribution of vasoactive intestinal peptide binding sites in the vertebrate central nervous system: a phylogenetic study.
Dietl MM; Hof PR; Martin JL; Magistretti PJ; Palacios JM
Brain Res; 1990 Jun; 520(1-2):14-26. PubMed ID: 2169952
[TBL] [Abstract][Full Text] [Related]
18. Effects of vasoactive intestinal polypeptide on neurones of the rat suprachiasmatic nuclei in vitro.
Reed HE; Cutler DJ; Brown TM; Brown J; Coen CW; Piggins HD
J Neuroendocrinol; 2002 Aug; 14(8):639-46. PubMed ID: 12153466
[TBL] [Abstract][Full Text] [Related]
19. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
Moreno D; Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 2000 Oct; 21(10):1543-9. PubMed ID: 11068102
[TBL] [Abstract][Full Text] [Related]
20. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
